Pharmaceutical companies by P/B ratio
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Viatris has the lowest figure of the 39 pharmaceutical companies ranked by P/B ratio, at 1.7, followed by Pfizer (1.8) and BioMarin Pharmaceutical (1.9). Figures as of 19 Nov 2026, 01:27 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 39
- Lowest
- Viatris1.7
- Median
- 6.8
- Combined market value
- HUF 1699.01T
- Countries
- 10
- Not ranked
- 22no P/B ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/B ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | ViatrisVTRS · Health Care | 1.7 | HUF 7.81T | HUF 6,810.79 | 0.83% down | 96% up | ||
| 2 | PfizerPFE · Health Care | 1.8 | HUF 53.71T | HUF 9,423.61 | 1.44% down | 14% up | ||
| 3 | BioMarin PharmaceuticalBMRN · Health Care | 1.9 | HUF 4T | HUF 20,630.53 | 4.99% up | 11% up | ||
| 4 | Elanco Animal HealthELAN · Health Care | 2.0 | HUF 4.48T | HUF 8,966.87 | 3.29% up | 20% up | ||
| 5 | Legend BiotechLEGN · Health Care | 2.5 | HUF 1.06T | HUF 5,457.37 | 0.87% up | 42% down | ||
| 6 | Edgewise TherapeuticsEWTX · Health Care | 2.8 | HUF 1.52T | HUF 13,893.62 | 1.59% down | 88% up | ||
| 7 | Regeneron PharmaceuticalsREGN · Health Care | 2.8 | HUF 32.85T | HUF 317,544.90 | 1.28% down | 36% up | ||
| 8 | Abbott LaboratoriesABT · Health Care | 3.5 | HUF 60.77T | HUF 35,088.35 | 0.22% down | 17% down | ||
| 9 | Dianthus TherapeuticsDNTH · Health Care | 3.8 | HUF 1.59T | HUF 28,203.68 | 3.45% down | 113% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 3.9 | HUF 8.26T | HUF 193,892.71 | 1.16% down | 23% up | ||
| 11 | Definium TherapeuticsDFTX · Health Care | 4.1 | HUF 1.34T | HUF 9,779.60 | 0.88% down | 169% up | ||
| 12 | Royalty PharmaRPRX · Health Care | 4.5 | HUF 13.26T | HUF 23,062.00 | 0.01% down | 78% up | ||
| 13 | Bristol-Myers SquibbBMY · Health Care | 5.2 | HUF 40.89T | HUF 20,002.51 | 2.92% down | 34% up | ||
| 14 | ErascaERAS · Health Care | 5.3 | HUF 1.62T | HUF 4,621.13 | 0.94% down | 403% up | ||
| 15 | Oruka TherapeuticsORKA · Health Care | 5.4 | HUF 2.18T | HUF 32,153.13 | 0.60% down | 241% up | ||
| 16 | Alnylam PharmaceuticalsALNY · Health Care | 5.5 | HUF 6.72T | HUF 50,174.20 | 4.54% down | 66% down | ||
| 17 | Ligand PharmaceuticalsLGND · Health Care | 6.2 | HUF 2.01T | HUF 100,318.17 | 1.67% up | 43% up | ||
| 18 | Vertex PharmaceuticalsVRTX · Health Care | 6.5 | HUF 45.68T | HUF 180,160.30 | 0.42% up | 27% up | ||
| 19 | VeradermicsMANE · Health Care | 6.6 | HUF 1.77T | HUF 41,932.73 | 0.62% down | 233% up | ||
| 20 | Praxis Precision MedicinesPRAX · Health Care | 6.8 | HUF 2.86T | HUF 102,494.40 | 0.04% up | 61% up | ||
| 21 | Merck & CoMRK · Health Care | 7.6 | HUF 114.07T | HUF 46,271.76 | 3.90% down | 51% up | ||
| 22 | Protagonist TherapeuticsPTGX · Health Care | 7.6 | HUF 2.79T | HUF 42,705.16 | 2.00% up | 46% up | ||
| 23 | Belite BioBLTE · Health Care | 8.0 | HUF 2.13T | HUF 52,467.97 | 0.94% down | 31% up | ||
| 24 | Johnson & JohnsonJNJ · Health Care | 8.1 | HUF 220.47T | HUF 91,583.02 | 2.15% down | 38% up | ||
| 25 | Corcept TherapeuticsCORT · Health Care | 8.9 | HUF 2.49T | HUF 22,766.46 | 3.25% down | 8% down | ||
| 26 | Spyre TherapeuticsSYRE · Health Care | 10.1 | HUF 3.24T | HUF 34,074.12 | 8.15% up | 286% up | ||
| 27 | ZoetisZTS · Health Care | 10.6 | HUF 11.68T | HUF 28,737.66 | 2.50% up | 29% down | ||
| 28 | Cogent BiosciencesCOGT · Health Care | 10.7 | HUF 1.63T | HUF 9,339.65 | 0.14% down | 20% down | ||
| 29 | Ionis PharmaceuticalsIONS · Health Care | 11.6 | HUF 1.53T | HUF 9,198.60 | 1.59% up | 64% down | ||
| 30 | Amneal PharmaceuticalsAMRX · Health Care | 14.3 | HUF 2.56T | HUF 7,348.14 | 3.60% up | 83% up | ||
| 31 | Madrigal PharmaceuticalsMDGL · Health Care | 14.7 | HUF 3.11T | HUF 133,690.39 | 5.67% down | 24% down | ||
| 32 | Summit TherapeuticsSMMT · Health Care | 14.9 | HUF 2.82T | HUF 3,526.30 | 1.59% down | 36% down | ||
| 33 | TG TherapeuticsTGTX · Health Care | 16.2 | HUF 3.36T | HUF 22,205.61 | 5.44% up | 107% up | ||
| 34 | Eli LillyLLY · Health Care | 30.6 | HUF 413.64T | HUF 464,379.99 | 2.32% down | 35% up | ||
| 35 | InsmedINSM · Health Care | 36.2 | HUF 8.83T | HUF 40,233.39 | 1.69% down | 40% down | ||
| 36 | Axsome TherapeuticsAXSM · Health Care | 66.8 | HUF 2.37T | HUF 45,002.29 | 1.43% down | 7% down | ||
| 37 | Rhythm PharmaceuticalsRYTM · Health Care | 93.8 | HUF 2.77T | HUF 39,978.16 | 2.08% up | 13% up | ||
| 38 | Arrowhead PharmaceuticalsARWR · Health Care | 121 | HUF 2.05T | HUF 14,477.98 | 0.28% up | 10% up | ||
| 39 | Travere TherapeuticsTVTX · Health Care | 213 | HUF 1.62T | HUF 16,872.50 | 1.68% down | 44% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 335.8 HUF). 22 companies have no P/B ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies have the lowest P/B ratio?
Viatris (1.7), Pfizer (1.8) and BioMarin Pharmaceutical (1.9) have the lowest P/B ratio of the 39 pharmaceutical companies ranked here as of 19 Nov 2026, 01:27 UTC.
How many pharmaceutical companies are in this ranking?
39 are ranked by P/B ratio. 22 more have no P/B ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 39 pharmaceutical companies ranked by P/B ratio have a combined market value of HUF 1699.01T as of 19 Nov 2026, 01:27 UTC.
What does ranking by P/B ratio measure?
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/B ratio”, data as of 19 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pb-ratio
Underlying data: Yahoo Finance; SEC EDGAR.